葫芦娃：董事长刘景萍涉嫌信息披露违法违规被证监会立案 近日，葫芦娃发布公告称，因公司及公司董事长刘景萍女士涉嫌信息披露违法违规，根据《中华人民共 和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司和刘景萍立案。 目前，公司各项生产经营活动正常有序开展，在立案调查期间，公司将积极配合中国证监会的相关调查 工作，并严格按照有关法律法规及监管要求履行信息披露义务。 SHR6508是一种新型钙敏感受体变构调节剂，拟用于治疗需接受血液透析的慢性肾脏病成年患者的继发 性甲状旁腺功能亢进症，目前正在进行Ⅲ期临床试验研究。钙敏感受体通过释放控制血液钙水平的甲状 旁腺激素（PTH）来监测并调控钙水平。由于对钙离子的敏感性增强，SHR6508给药后可减少继发性甲 状旁腺功能亢进症血液透析患者的PTH分泌。 翰森制药须向恒瑞医药支付首付款人民币3000万元。恒瑞医药有资格获得监管里程碑付款及与许可产品 纳入国家医保目录相关的商业里程碑付款最高可达人民币1.9亿元。有权根据季度净销售额获得阶梯 式、最高9%比例的销售提成。 悦康药业：申请H股发行并赴港上市同步刊登申请资料 近日，悦康药业集团股份有限公司发布公告 ...

#方大炭素终止参与杉杉重整#【方大炭素：终止参与杉杉集团及其全资子公司实质合并重整】方大炭素 公告称，公司于2025年11月24日同意参与杉杉集团有限公司及其全资子公司宁波朋泽贸易有限公司的实 质合并重整投资人招募。然而，由于尽职调查时间短、不充分，无法对标的资产做出合理价值判断。同 时，结合公司在新材料、新能源领域的战略规划，公司决定终止参与重整事项。这一决定不会对公司的 生产经营及财务状况产生不利影响。（智通财经） ...

Core Viewpoint - The company aims to become a world-class smart electric vehicle manufacturer in the next decade, driven by technological innovation and global expansion [1][9]. Group 1: Company Overview - The founder and CEO, Zhu Jiangming, reflected on the company's ten-year journey in the automotive industry, emphasizing the importance of maintaining control by the founding team despite new investments [2]. - As of now, the company has delivered over 1.2 million vehicles, with an expected annual sales volume of nearly 600,000 units in 2025, positioning it as a leader among new automotive manufacturers [2]. Group 2: Historical Challenges - The company faced significant challenges in its early years, describing the past decade as "nine lives," indicating the difficulties encountered in achieving profitability and market acceptance [3]. - The initial market response to the first model, S01, was lukewarm, leading to financial and market pressures until the successful launch of the T03 model in 2020, which validated the company's strategy of offering high-value products [5]. Group 3: Product Development and Financial Milestones - The launch of the C11 model in September 2021 marked a significant turning point, offering strong product capabilities and achieving a notable market presence [6]. - In 2023, the company achieved a milestone by reaching a positive gross margin of 0.5%, indicating its first profitable year in vehicle manufacturing [6]. Group 4: Future Goals and Strategies - The company has set an ambitious target of achieving annual sales of 4 million vehicles in the next decade, supported by a clear strategy that includes expanding its product line and accelerating global operations [9][12]. - Plans include launching a full range of vehicles from A0 to D class over the next three years and establishing a presence in key international markets through partnerships and local operations [12]. Group 5: Challenges Ahead - The company will face intense competition in the mainstream market segment priced between 150,000 to 250,000 yuan, with new entrants like Huawei and Xiaomi [14]. - Global expansion will require adaptation to local regulations, consumer habits, and infrastructure, alongside the need to build multiple factories to support the production of 4 million vehicles [14].

1月4日，交通运输部发布《关于加快交通运输公共数据资源开发利用的实施意见》。其中提到，加强公 共数据资源采集与归集。依托交通基础设施数字化转型升级，运用物联网等技术提升交通基础设施及运 载装备数据采集智能化水平。建立健全部省协同数据归集机制，实现行业重点数据在国家综合交通运输 信息平台高效集中汇聚。以公共数据资源目录为基础，推动数据资源"按需归集、应归尽归"。（新浪财 经） 编辑丨安安 作者丨彭鑫 ...

Core Insights - The New Year's holiday in 2026 has significantly boosted tourism consumption, with a notable increase in bookings for flights, hotels, and vacation rentals, driven by the "please take 3 days off and rest for 8" holiday trend [1][2] Domestic Travel - The domestic travel market is characterized by a blend of short-term micro-vacations and long-term deep travel, with core city clusters actively engaging in consumption [2] - Popular destinations include Northeast China, Hainan, Yunnan, Xinjiang, and Sichuan, with a 176% year-on-year increase in bookings for winter sun destinations [2] - The trend of "cross-regional travel" is evident, with over 50% of bookings for southern destinations made by northern travelers [2] Consumption Trends - There is a diversification in consumption scenarios, with events driving interest in various destinations, such as the popularity of Chinese-themed amusement parks [3] - The demand for high-quality accommodations and personalized services has increased, with family and child-friendly options seeing significant growth [4] - Bookings for family-oriented vacation rentals have surged, with orders for two-bedroom and larger properties increasing by 13% and 227% respectively [4] External Influences - The implementation of Hainan's duty-free shopping policy has led to a 20% increase in visitors since December 2025, with hotel and rental occupancy rates more than doubling [5] Cross-Border Travel - The cross-border travel market is experiencing a dual recovery, with both outbound and inbound tourism gaining momentum [6][7] - Popular outbound travel themes include island vacations and destinations with visa-free access, with significant growth in bookings from non-first-tier cities [7] - Inbound tourism is also on the rise, with a 5-fold increase in foreign visitors to Sanya, and a diverse range of cities being popular among international travelers [8]

Core Viewpoint - Furuimei Medical has announced a rectification report following regulatory scrutiny regarding its internal control and revenue recognition practices, as it prepares for an H-share listing in Hong Kong [1][5]. Group 1: Regulatory Actions and Company Response - On December 10, 2025, Furuimei Medical received a decision from the Inner Mongolia Regulatory Bureau, mandating rectification of issues related to inadequate internal controls over overseas subsidiaries and irregular revenue recognition [3]. - The company has developed a management approach for overseas subsidiaries to enhance internal controls and risk management, clarifying management requirements in strategic planning and compliance [1][2]. - Furuimei Medical's audit department has issued audit notices to key overseas subsidiaries and engaged professional institutions for specialized internal audits to ensure compliance and effectiveness [2]. Group 2: Revenue Recognition Issues - The regulatory decision highlighted that Furuimei Medical recognized revenue prematurely, affecting financial disclosures for 2023 and 2024, with amounts of 240.89 million, 288.10 million, 567.03 million, and 134.17 million respectively [3]. - The company has implemented measures to align revenue recognition with accounting standards, focusing on control transfer and customer acceptance as criteria for financial processing [4]. Group 3: Strategic Developments - Following the regulatory scrutiny, Furuimei Medical announced a name change and plans for an H-share listing on the Hong Kong Stock Exchange to enhance its competitive position and access to international capital [5][6]. - The company has changed its stock name from "Furuimei Co., Ltd." to "Furuimei Medical" to better reflect its strategic focus and brand image [6]. Group 4: Company Overview and Performance - Furuimei Medical, established in 1998, operates in the medical sector, focusing on drug production, diagnostic equipment development, and medical services, with a global presence in over 100 countries [7]. - For the first nine months of 2025, Furuimei Medical reported revenue of 1.101 billion, a year-on-year increase of 12.37%, and a net profit attributable to shareholders of 112 million, up 9.69% [8].

#铜陵有色厄瓜多尔工程延期#【铜陵有色：米拉多铜矿二期工程延期 预计将对公司2026年的经营业绩 产生一定影响】铜陵有色公告称，控股子公司中铁建铜冠投资有限公司的米拉多铜矿二期工程预计将延 期。该工程原计划于2025年6月建成，2025年7月至12月进行试生产，2026年初正式投产。然而，由于厄 瓜多尔政治局势波动，人事变动频繁，导致《采矿合同》签署进度受影响，正式投产工作需待《采矿合 同》签署后方可实施。目前，米拉多铜矿二期工程正式投产时间尚不确定，预计将对公司2026年的经营 业绩产生一定影响。（智通财经） 证券代码:000630 证券简称:铜陵有色 公告编号:2026-001 铜陵有色金属集团股份有限公司 (一)项目建设情况 2022年,中铁建铜冠着手规划厄瓜多尔米拉多铜矿二期工程(以下简称"米 拉多铜矿二期工程")建设,依据其可行性研究报告计划安排,米拉多铜矿二期 工程 2025年 6 月建成:2025年 7-12 月,进行试生产作业:2026年初正式投产。 按照规划,米拉多铜矿二期工程于 2023年8月启动主体工程建设,2025年5 月基本建成,用时 22个月,在国外同类工程中建设效率较高;项目于 ...

1月4日，Grok新版本已发布，用户可在iOS上将软件更新至1.3.28版本，本次更新主要优化了Imagine视 频生成等功能。(界面) ...

Core Viewpoint - Yifeng Pharmacy has indicated that due to multiple factors such as the economic environment and industry cycles, the company will focus on improving operational quality, leading to a reduction in store openings and acquisition plans, resulting in a slowdown in revenue growth compared to previous periods [1] Group 1: Company Performance - For the period from January to September 2025, Yifeng Pharmacy achieved revenue of 17.286 billion yuan, representing a year-on-year growth of 0.39% [1] - The company reported a net profit attributable to shareholders of 1.225 billion yuan, which is a year-on-year increase of 10.27% [1] Group 2: Industry Outlook - The fundamental development logic of the industry remains unchanged, driven by factors such as accelerated population aging, medical reform separating medicine from medical services, and increased industry concentration [1] - Retail pharmacies are expected to continue to enhance their channel and social value as important entry points for community health [1] - The retail pharmacy industry is anticipated to experience new development opportunities with the ongoing innovation in diversified operations and the maturation of new retail models both online and offline [1]

Core Insights - Tianjin Zhonghe Gene Technology Co., Ltd. has recently announced additional strategic investment from Changtou Hejia Fund following the completion of its Pre-A+ round financing, indicating strong market recognition of the company's strategic execution and growth potential [1] - Established in 2022 in Tianjin, China, Zhonghe Gene is a national high-tech enterprise focused on the development and commercialization of green synthesis equipment based on biological DNA synthesis technology [1] Investment Highlights - The recent investment reflects investors' confidence in the company and their long-term outlook [1] - The company has demonstrated significant strategic execution capabilities, which have been acknowledged by the capital market [1]